The World Health Organization (WHO) on Friday reported that it has suspended Gilead’s remdesivir from its prequalification list – an official list of medicines that is used as a benchmark for procurement by developing countries.
Not long ago, World Health Organization issued guidance against the usage of remdesivir in hospitalized COVID-19 patients.
“Yes we have suspended it from the PQ (prequalification list),” Tarik Jasarevic said in an emailed response to Reuters. “The suspension is a signal to countries that WHO, in compliance with the treatment guidelines, does not recommend countries procure the drug for COVID.”
He also denied any awareness of WHO regarding any international procurers providing the drug to low and middle-income countries.
Experts have concluded that remdesivir showed no impact on mortality or meaningful out for COVID-19 patients. There has been scepticism for months regarding the use of Remdesivir for Corona patients.